CC
PVCT

Cannell & Co’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Cannell & Co’s Portfolio PVCT Stock Details PVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-90,000
Closed -$52K – 277
2015
Q3 		$52K Hold
90,000
– – ﹤0.01% 263
2015
Q2 		$49K Buy
+90,000
New +$73.4K ﹤0.01% 266

Other funds holding PVCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HFBOT
Home Federal Bank of Tennessee Knoxville, Tennessee $463M AUM 24.62% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

Cannell & Co's PVCT Position: Q4 2015 in Review

Cannell & Co sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q4 2015, closing a stake of 90,000 shares — an estimated $52K sold.

Cannell & Co first reported a position in PVCT in Q2 2015 and held it in 2 quarters. The position peaked at $52K in Q3 2015. 43 funds tracked by Wall St. Rank hold PVCT as of Q4 2015.

  • Cannell & Co reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q4 2015 after selling out during the quarter.
  • Cannell & Co sold 90,000 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q4 2015, an estimated $52K.
  • Cannell & Co first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q2 2015 and held it in 2 quarters.
  • Cannell & Co's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $52K in Q3 2015.
  • 43 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q4 2015.

Based on Cannell & Co's 13F filing for Q4 2015, filed 11 Feb 2016.